Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors

ACS Chemical Biology

Volumn 8, Issue 11, 2013, Pages 2550-2560

  Gryder, Berkley E ^a   Akbashev, Michelle J ^a   Rood, Michael K ^a   Raftery, Eric D ^a   Meyers, Warren M ^c   Dillard, Paulette ^b   Khan, Shafiq ^b   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b CLARK ATLANTA UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; MALE; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; BIOLOGICAL MODEL; CELL PROLIFERATION; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IC50; METABOLISM; PROSTATIC NEOPLASMS; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84887981384     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400542w     Document Type: Article

References (54)

1. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012) Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 11, 384-400
2. Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., and Mazitschek, R. (2010) Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 6, 238-243
3. Perry, A. S., Watson, R. W. G., Lawler, M., and Hollywood, D. (2010) The epigenome as a therapeutic target in prostate cancer Nat. Rev. Urol. 7, 668-680
4. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications Nature 403, 41-45
5. Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006) Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 5, 769-784
6. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., and Schreiber, S. L. (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. U.S.A. 100, 4389-4394
7. Gu, W. and Roeder, R. G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 90, 595-606
8. Brochier, C., Dennis, G., Rivieccio, M. A., McLaughlin, K., Coppola, G., Ratan, R. R., and Langley, B. (2013) Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons J. Neurosci. 33, 8621-8632
9. Marzio, G., Wagener, C., Gutierrez, M. I., Cartwright, P., Helin, K., and Giacca, M. (2000) E2F family members are differentially regulated by reversible acetylation J. Biol. Chem. 275, 10887-10892
10. Gryder, B. E., Sodji, Q. H., and Oyelere, A. K. (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed Future Med. Chem. 4, 505-524
11. Bradley, D., Rathkopf, D., Dunn, R., Stadler, W. M., Liu, G., Smith, D. C., Pili, R., Zwiebel, J., Scher, H., and Hussain, M. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium Cancer 115, 5541-5549
12. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., Flaig, T. W., Flechon, A., Mainwaring, P., Fleming, M., Hainsworth, J. D., Hirmand, M., Selby, B., Seely, L., de Bono, J. S., and Investigators, A. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 367, 1187-1197
13. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy Nat. Med. 10, 33-39
14. Papatsoris, A. G., Karamouzis, M. V., and Papavassiliou, A. G. (2005) Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC) Curr. Med. Chem. 12, 277-296
15. Linja, M. J., Savinainen, K. J., Saramaki, O. R., Tammela, T. L. J., Vessella, R. L., and Visakorpi, T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res. 61, 3550-3555
16. Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cal, L., Aparicio, A., Dorow, S., Arora, V., Shao, G., Qian, J., Zhao, H., Yang, G. B., Cao, C. Y., Sensintaffar, J., Wasielewska, T., Herbert, M. R., Bonnefous, C., Darimont, B., Scher, H. I., Smith-Jones, P., Klang, M., Smith, N. D., De Stanchina, E., Wu, N., Ouerfelli, O., Rix, P. J., Heyman, R. A., Jung, M. E., Sawyers, C. L., and Hager, J. H. (2012) ARN-509: A novel antiandrogen for prostate cancer treatment Cancer Res. 72, 1494-1503
17. Jones, J. O., An, W. F., and Diamond, M. I. (2009) AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization ACS Chem. Biol. 4, 199-208
18. Chen, Y., Clegg, N. J., and Scher, H. I. (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 10, 981-991
19. Chen, P. C., Patil, V., Guerrant, W., Green, P., and Oyelere, A. K. (2008) Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group Bioorg. Med. Chem. 16, 4839-4853
20. Van Dort, M. E. and Jung, Y. W. (2001) Synthesis and structure-activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands Bioorg. Med. Chem. Lett. 11, 1045-1047
21. Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., and Wongvipat, J. (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 53, 2779-2796
22. Sharifi, N., Hamel, E., Lill, M. A., Risbood, P., Kane, C. T., Hossain, M. T., Jones, A., Dalton, J. T., and Farrar, W. L. (2007) A bifunctional colchicinoid that binds to the androgen receptor Mol. Cancer Ther. 6, 2328-2336
23. Cogan, P. S. and Koch, T. H. (2003) Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate J. Med. Chem. 46, 5258-5270
24. Dreaden, E. C., Gryder, B. E., Austin, L. A., Tene Defo, B. A., Hayden, S. C., Pi, M., Quarles, L. D., Oyelere, A. K., and El-Sayed, M. A. (2012) Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells Bioconjugate Chem. 23, 1507-1512
25. Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., and Deshaies, R. J. (2003) Development of protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell. Proteomics 2, 1350-1358
26. Himo, F., Lovell, T., Hilgraf, R., Rostovtsev, V. V., Noodleman, L., Sharpless, K. B., and Fokin, V. V. (2005) Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates J. Am. Chem. Soc. 127, 210-216
27. Bock, V. D., Hiemstra, H., and van Maarseveen, J. H. (2006) Cu-I-catalyzed alkyne-azide ″click″ cycloadditions from a mechanistic and synthetic perspective Eur. J. Org. Chem. 51-68
28. Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z. X., Scott, G. K., and Benz, C. C. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents Annu. Rev. Pharmacol. Toxicol. 45, 495-528
29. Inks, E. S., Josey, B. J., Jesinkey, S. R., and Chou, C. J. (2012) A novel class of small molecule inhibitors of HDAC6 ACS Chem. Biol. 7, 330-338
30. Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., and Fletterick, R. J. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface PLoS Biol. 2, e274
31. Wakeling, A. E., Furr, B. J. A., Glen, A. T., and Hughes, L. R. (1981) Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens J. Steroid Biochem. 15, 355-359
32. Avvakumov, G. V., Cherkasov, A., Muller, Y. A., and Hammond, G. L. (2010) Structural analyses of sex hormone-binding globulin reveal novel ligands and function Mol. Cell. Endocrinol. 316, 13-23
33. Yang, J., Bohl, C. E., Nair, V. A., Mustafa, S. M., Hong, S. S., Miller, D. D., and Dalton, J. T. (2006) Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer J. Pharmacol. Exp. Ther. 317, 402-408
34. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95, 927-937
35. Zhou, J., Liu, B., Geng, G., and Wu, J. H. (2010) Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens Proteins: Struct., Funct., Bioinf. 78, 623-637
36. Heldring, N., Pawson, T., McDonnell, D., Treuter, E., Gustafsson, J. A., and Pike, A. C. W. (2007) Structural insights into corepressor recognition by antagonist-bound estrogen receptors J. Biol. Chem. 282, 10449-10455
37. Wang, L., Zuercher, W. J., Consler, T. G., Lambert, M. H., Miller, A. B., Orband-Miller, L. A., McKee, D. D., Willson, T. M., and Nolte, R. T. (2006) X-ray crystal structures of the estrogen-related receptor-γ ligand binding domain in three functional states reveal the molecular basis of small molecule regulation J. Biol. Chem. 281, 37773-37781
38. Levine, P. M., Lee, E., Greenfield, A., Bonneau, R., Logan, S. K., Garabedian, M. J., and Kirshenbaum, K. (2012) Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells ACS Chem. Biol. 7, 1693-1701
39. Shen, H. C., Shanmugasundaram, K., Simon, N. I., Cai, C. M., Wang, H. Y., Chen, S., Balk, S. P., and Rigby, A. C. (2012) In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer Mol. Endocrinol. 26, 1836-1846
40. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., and Sawyers, C. L. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324, 787-790
41. Jia, L., Berman, B. P., Jariwala, U., Yan, X., Cogan, J. P., Walters, A., Chen, T., Buchanan, G., Frenkel, B., and Coetzee, G. A. (2008) Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity PLoS One 3, e3645
42. Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., and Wang, Z. (2009) HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Mol. Endocrinol. 23, 1963-1972
43. Kreis, W., Budman, D. R., and Calabro, A. (2001) A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents Cancer Chemother. Pharmacol. 47, 78-82
44. Kuruma, H., Matsumoto, H., Shiota, M., Bishop, J., Lamoureux, F., Thomas, C., Briere, D., Los, G., Gleave, M., Fanjul, A., and Zoubeidi, A. (2013) A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Mol. Cancer Ther. 12, 567-576
45. Danquah, M., Duke, C. B., Patil, R., Miller, D. D., and Mahato, R. I. (2012) Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer Pharm. Res. 29, 2079-2091
46. Marrocco, D. L., Tilley, W. D., Bianco-Miotto, T., Evdokiou, A., Scher, H. I., Rifkind, R. A., Marks, P. A., Richon, V. M., and Butler, L. M. (2007) Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol. Cancer Ther. 6, 51-60
47. Attar, R. M., Takimoto, C. H., and Gottardis, M. M. (2009) Castration-resistant prostate cancer: Locking up the molecular escape routes Clin. Cancer Res. 15, 3251-3255
48. Watson, P. A., Chen, Y. N. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., and Sawyers, C. L. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc. Natl. Acad. Sci. U.S.A. 107, 16759-16765
49. Vo, B. T., Cody, B., Cao, Y., and Khan, S. A. (2012) Differential role of SloanKettering Institute (Ski) protein in Nodal and transforming growth factor-beta (TGF-beta)-induced Smad signaling in prostate cancer cells Carcinogenesis 33, 2054-2064
50. Hammond, G. L. and Lahteenmaki, P. L. A. (1983) A versatile method for the determination of serum cortisol binding globulin and sex hormone binding globulin binding capacities Clin. Chim. Acta 132, 101-110
51. Taylor, J., Rohatgi, P., Spencer, H. T., Doyle, D., and Azizi, B. (2010) Characterization of a molecular switch system that regulates gene expression in mammalian cells through a small molecule BMC Biotechnol. 10, 15
52. Gryder, B. E., Rood, M. K., Johnson, K. A., Patil, V., Raftery, E. D., Yao, L.-P. D., Rice, M., Azizi, B., Doyle, D., and Oyelere, A. K. (2013) Histone deacetylase inhibitors equipped with estrogen receptor modulation activity J. Med. Chem. 56, 5782-5796
53. Trott, O. and Olson, A. J. (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 31, 455-461
54. Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M. S., Ma, A. A. K., Miner, J. N., and Diamond, M. I. (2005) The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions Proc. Natl. Acad. Sci. U.S.A. 102, 9802-9807